Abstract: The present invention provides a basal cell culture medium and a feed medium with novel amino acid ratios and/or iron choline citrate as iron carrier that result in improved performance of mammalian cell culture processes, such as CHO cultivation and protein production processes, in particular in increased product titer (e.g. of monoclonal antibodies). Also provided are methods for culturing mammalian cells and producing a protein of interest using said basal cell culture medium and optionally feed medium. The invention also provides for a medium platform that comprises (i) the basal cell culture medium and (ii) the feed medium.

Abstract: The present invention provides a basal cell culture medium and a feed medium with novel amino acid ratios and/or iron choline citrate as iron carrier that result in improved performance of mammalian cell culture processes, such as CHO cultivation and protein production processes, in particular in increased product titer (e.g. of monoclonal antibodies). Also provided are methods for culturing mammalian cells and producing a protein of interest using said basal cell culture medium and optionally feed medium. The invention also provides for a medium platform that comprises (i) the basal cell culture medium and (ii) the feed medium.

Abstract: The present invention provides a basal cell culture medium and a feed medium with novel amino acid ratios and/or iron choline citrate as iron carrier that result in improved performance of mammalian cell culture processes, such as CHO cultivation and protein production processes, in particular in increased product titer (e.g. of monoclonal antibodies). Also provided are methods for culturing mammalian cells and producing a protein of interest using said basal cell culture medium and optionally feed medium. The invention also provides for a medium platform that comprises (i) the basal cell culture medium and (ii) the feed medium.

Abstract: The various technologies presented herein relate to assisting a prescriber in obtaining and maintaining Risk Evaluation and Mitigation Strategy (REMS) compliance. A centralized approach is presented for obtaining REMS compliance data from a drug manufacturer, federal regulator, etc., and based on identifying one or more REMS medications associated with a prescriber, compliance of the prescriber with regard to the REMS compliance data for the one or more REMS medications can be determined. Interaction and notifications, etc., can be performed utilizing internet access. In the event of a prescriber failing a compliance requirement, one or more actions can be identified to facilitate bringing the prescriber into REMS compliance. REMS compliance data can be shared with the drug manufacturer, regulatory body, etc., to facilitate understanding of success of REMS compliance. Stored REMS compliance data can be forwarded to a third party.